About this paper
Only a few months ago, the conversation about sharing clinical trial data was largely an argument of concerns and speculations against the idea. Spurred in part by growing momentum from government entities, the mood among life sciences companies has shifted to one of positive intention. It's just a matter of determining how to go about it. This article summarizes discussion on the topic with industry leaders at the second installment of the Clinical Trial Data Transparency Forum, sponsored by SAS, in February 2014.